By Counterforce Health Team in Cosentyx (secukinumab) —

Coding That Helps Get Cosentyx (secukinumab) Approved in Texas with Aetna CVS Health (ICD-10, HCPCS/J-Code, NDC)

Answer Box: Fastest Path to Cosentyx (secukinumab) Approval in Texas

Aetna CVS Health requires prior authorization for Cosentyx (secukinumab) in Texas with specific coding requirements. Use ICD-10 L40.0 (plaque psoriasis), L40.5X (psoriatic arthritis), or M45 (ankylosing spondylitis) with detailed documentation. For IV administration, bill under HCPCS J3247 (effective July 2024) on the medical benefit. Subcutaneous forms go through CVS Caremark specialty pharmacy. Start today: Gather complete prior therapy records and submit via Aetna's provider portal with proper ICD-10 and severity documentation. Appeals must be filed within 180 days if denied.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit Pathways
  2. ICD-10 Mapping for Cosentyx Indications
  3. Product Coding: HCPCS, J-Codes, and NDC Numbers
  4. Clean Prior Authorization Request Anatomy
  5. Frequent Coding Pitfalls to Avoid
  6. Verification with Aetna CVS Health Resources
  7. Pre-Submission Audit Checklist
  8. Appeals Process for Texas
  9. FAQ

Coding Basics: Medical vs. Pharmacy Benefit Pathways

Understanding which benefit covers Cosentyx (secukinumab) determines your coding approach with Aetna CVS Health in Texas.

Medical Benefit Path

  • IV Cosentyx administration in office/hospital settings
  • Bill with: HCPCS J3247 + NDC + appropriate modifiers
  • Forms: CMS-1500 or UB-04 with procedure codes
  • Prior auth: Through Aetna medical benefits department

Pharmacy Benefit Path

  • Subcutaneous Cosentyx for self-injection
  • Processed by: CVS Caremark specialty pharmacy
  • Bill with: NDC numbers only (no J-codes)
  • Prior auth: Through CVS Caremark PA system at 1-866-752-7021
Tip: Most Cosentyx prescriptions are subcutaneous and flow through the pharmacy benefit. Only provider-administered IV formulations use the medical benefit pathway.

ICD-10 Mapping for Cosentyx Indications

Precise ICD-10 coding supports medical necessity for Aetna CVS Health prior authorization in Texas.

Primary ICD-10 Codes

Condition ICD-10 Code Documentation Requirements
Plaque Psoriasis L40.0 Body surface area (BSA), PASI score, prior therapy failures
Psoriatic Arthritis L40.5X Joint involvement sites, functional impact, radiographic changes
Ankylosing Spondylitis M45 Spinal mobility measures, inflammatory markers, imaging findings
Hidradenitis Suppurativa L73.2 Hurley stage, lesion count, flare frequency

Documentation Words That Support Coding

For L40.0 (Plaque Psoriasis):

  • "Moderate to severe plaque psoriasis"
  • "BSA >10%" or specific percentage
  • "Failed topical therapy" or "inadequate response to phototherapy"
  • "Significant functional impairment"

For L40.5X (Psoriatic Arthritis):

  • "Active psoriatic arthritis with [X] joints involved"
  • "Morning stiffness >30 minutes"
  • "Enthesitis" or "dactylitis" when present
  • "Inadequate response to MTX/DMARD therapy"

For M45 (Ankylosing Spondylitis):

  • "Active axial spondyloarthritis"
  • "Limited spinal mobility"
  • "Elevated CRP/ESR during active disease"
  • "Failed adequate trial of NSAIDs"
Note: Avoid unspecified codes like L40.9 when detailed diagnosis is available. Aetna CVS Health reviews documentation for specificity and severity indicators.

Product Coding: HCPCS, J-Codes, and NDC Numbers

HCPCS J-Codes for IV Cosentyx

J3247 - Injection, secukinumab, intravenous, 1 mg

  • Effective: July 1, 2024
  • Units: Bill total mg administered (e.g., 300 mg = 300 units)
  • Replaces: Previous codes C9166 and J3590

Required Modifiers

  • JA modifier: Identifies administered drug amount
  • JW modifier: Required for any wasted drug from single-dose vials

NDC Numbers for Billing

  • IV Cosentyx: 00078-1168-61 (125 mg/5 mL vial)
  • SC Cosentyx: Multiple NDCs depending on pen/syringe configuration

Units Calculation Example

Patient receives 300 mg IV Cosentyx:

  • HCPCS: J3247
  • Units: 300 (representing 300 mg)
  • NDC: 00078-1168-61
  • Modifiers: JA (if no waste), JA + JW (if waste occurred)

Clean Prior Authorization Request Anatomy

Essential Components for Aetna CVS Health PA

1. Patient Demographics

  • Full name, DOB, member ID
  • Texas address confirmation
  • Primary care provider information

2. Clinical Information

  • ICD-10 code with 5th/6th digit specificity
  • Diagnosis date and severity documentation
  • Prior therapy history with dates, doses, duration, outcomes

3. Prescriber Details

  • Specialist credentials (dermatology/rheumatology preferred)
  • NPI number and Texas license
  • Office contact information

4. Drug-Specific Details

  • Cosentyx dosing: 300 mg SC every 4 weeks (typical maintenance)
  • NDC number for specific formulation requested
  • Quantity: Align with FDA-approved dosing intervals

5. Supporting Documentation

  • TB screening results (TST or IGRA)
  • Laboratory values (CBC, liver function if relevant)
  • Chart notes documenting prior treatment failures

Example PA Request Line

Patient: Jane Smith (ID: ABC123456789)
Diagnosis: L40.52 - Psoriatic arthritis, multiple sites
Drug: Cosentyx (secukinumab) 300mg/2mL prefilled pen
NDC: [specific NDC from package]
Quantity: #2 pens per 28 days
Prior therapies: Failed MTX 25mg/week x 6 months (inadequate response), 
discontinued Humira due to injection site reactions
Prescriber: Dr. John Doe, Rheumatology (NPI: 1234567890)

Frequent Coding Pitfalls to Avoid

Unit Conversion Errors

  • Wrong: Billing J3247 as "1 unit" for 300 mg dose
  • Correct: Bill J3247 as "300 units" for 300 mg dose

Mismatched Benefit Pathways

  • Wrong: Submitting IV Cosentyx through pharmacy benefit
  • Correct: IV through medical benefit, SC through pharmacy benefit

Missing Start Dates

  • Issue: PA requests without clear treatment start date
  • Fix: Include "anticipated start date" within 30 days of approval

Incomplete Prior Therapy Documentation

  • Wrong: "Patient tried biologics previously"
  • Correct: "Failed adalimumab 40mg Q2W x 4 months due to inadequate response (PASI improved from 18 to 12, <50% improvement)"

NDC Reporting Errors

  • Using 10-digit instead of 11-digit NDC format
  • Reporting NDC for wrong formulation (pen vs. syringe)

Verification with Aetna CVS Health Resources

Official Aetna Policy Documents

CVS Caremark Resources

  • Provider portal: Caremark.com for pharmacy benefit PAs
  • Phone: 1-866-752-7021 for urgent PA requests
  • Fax: 1-888-267-3277 for PA submissions

Cross-Check Steps

  1. Verify current formulary status on Aetna provider portal
  2. Confirm step therapy requirements for patient's specific plan
  3. Check quantity limits against requested supply
  4. Validate ICD-10 codes support medical necessity
Important: Aetna CVS Health updates policies quarterly. Always verify current criteria before submission.

Pre-Submission Audit Checklist

Clinical Documentation Review

  • ICD-10 code matches documented diagnosis
  • Prior therapy trials documented with specific drugs, doses, durations
  • Contraindications or intolerance clearly stated
  • Disease severity quantified (BSA, joint counts, functional measures)
  • TB screening completed and documented

Administrative Requirements

  • PA form completely filled with no blank required fields
  • Prescriber signature and date within 30 days
  • Patient demographics match insurance card exactly
  • NDC number verified against product packaging

Texas-Specific Requirements

  • Texas prescriber license verified and current
  • Patient address confirms Texas residency
  • Understanding of 180-day appeal deadline for denials
  • Emergency supply options identified if urgent need

Appeals Process for Texas

When Aetna CVS Health denies Cosentyx prior authorization in Texas, you have specific rights and timelines.

Internal Appeal Timeline

  • Deadline: 180 calendar days from denial notice
  • Standard review: 30-45 business days
  • Expedited review: 72 hours for urgent cases
  • Submit to: Aetna appeals department via provider portal or fax

External Review (IRO) Process

  • Trigger: After internal appeal denial
  • Deadline: 4 months from final internal denial
  • Timeline: 30 days standard, 72 hours expedited
  • Cost: Covered by Aetna (no patient cost)
  • Decision: Binding on Aetna if overturned

Required Appeal Documents

  1. Original denial letter with reference number
  2. Updated medical necessity letter addressing denial reasons
  3. Additional clinical evidence (labs, imaging, specialist notes)
  4. Peer-reviewed literature supporting Cosentyx use
  5. Patient impact statement documenting disease burden

Counterforce Health specializes in transforming insurance denials into targeted, evidence-backed appeals. Their platform analyzes denial letters and plan policies to draft point-by-point rebuttals aligned with Aetna's specific requirements, increasing approval rates for complex biologics like Cosentyx.

Texas External Review Contact

  • Texas Department of Insurance: 1-800-252-3439
  • IRO Information Line: 1-866-554-4926
  • Online: TDI.texas.gov for external review forms

FAQ

How long does Aetna CVS Health prior authorization take for Cosentyx in Texas? Standard PA decisions typically take 15-30 business days. Expedited requests for urgent medical needs are processed within 72 hours. Submit complete documentation to avoid delays.

What if Cosentyx is non-formulary on my Aetna plan? Request a formulary exception with documentation of medical necessity and failure of preferred alternatives. Include comparative effectiveness data and clinical rationale for Cosentyx over formulary options.

Can I get an emergency supply while PA is pending? Texas law allows pharmacies to provide 72-hour emergency supplies for ongoing therapy. For new prescriptions, work with your prescriber to request expedited PA review citing urgent medical need.

Does step therapy apply if I failed biologics in another state? Yes, documented failures from any location count toward step therapy requirements. Ensure medical records clearly document drug names, doses, duration, and reasons for discontinuation.

What coding is required for hidradenitis suppurativa indication? Use ICD-10 L73.2 with documentation of Hurley stage, lesion count, and prior therapy failures. Include antibiotic trials and surgical interventions attempted before biologic therapy.

How do I request peer-to-peer review with Aetna? Contact Aetna provider services at 1-866-752-7021 to schedule peer-to-peer discussion. Have clinical notes and denial letter available. Document outcomes and follow up in writing.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with healthcare providers and verify current insurance policies. Coverage decisions are made by Aetna CVS Health based on individual medical circumstances and plan benefits. For personalized assistance with complex prior authorizations and appeals, consider working with Counterforce Health, which helps patients and clinicians navigate insurance denials with evidence-backed appeal strategies.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.